Jeffrey Anderson

Bristol-Myers Squibb (United States) ORCID: 0000-0002-0902-5533

3

h-index

3

Publications

5,931

Citations

Publications

3 shown

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry , Bruno Sangro , Thomas Yau +18 more

2017 The Lancet 4168 citations

CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

Thomas Yau , J.W. Park , Richard S. Finn +17 more

2019 Annals of Oncology 634 citations

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

Thomas Yau , Yoon‐Koo Kang , Tae‐You Kim +18 more

ClinicalTrials.gov Identifier: NCT01658878.

2020 JAMA Oncology 1129 citations

Frequent Co-Authors

Anthony B. El-Khoueiry

USC Norris Comprehensive Cancer Center

Bruno Sangro

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas

Thomas Yau

University of Hong Kong

Todd S. Crocenzi

Providence Health & Services

Masatoshi Kudo

Kindai University

Chiun Hsu

National Taiwan University Hospital

Researcher Info

h-index: 3
Publications: 3
Citations: 5,931
Institution: Bristol-Myers Squibb (United States)

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-0902-5533

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.

Academic Output Over Time